Immuneering Corp. Class A IMRX 深 沪
等待开盘 05-23 09:30:00 美东时间
5.7488
+0.529
+10.13%
华盛通- 最 高6.8839
- 今 开5.99
- 成交量 789.33万股
- 最 低 5.56
- 昨 收 5.22
- 总市值 3.72亿
- 52周最高 10.08
- 市盈率 静 --
- 换手率 12.20%
- 52周最低 1.66
- 委 比 4.39%
- 总股本 6469.74万
- 历史最高 33.99
- 量 比 18.74
- 振 幅 25.36%
- 历史最低 1.00
- 每 手 1
- 风险率 1.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immuneering Reveals 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy; Tolerability Profile Consistent With Prior Updates; Only Two Categories Of Grade 3 Or Higher Treatment-Related Adverse Events Observed In ≥10% Of Patients, Both Chemotherapy-Related
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival (OS) in first-line
05-22 05:05
Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 50 percent increase over losses of $(0.42) per share from the same
05-15 19:38
Immuneering To Present Updated Data From Phase 2a Clinical Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Pancreatic Cancer At 2026 ASCO Annual Meeting
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -- The ASCO presentation will highlight
04-22 04:10
Immuneering To Present Atebimetinib ctDNA Data Showing Durable Tumor Shrinkage At AACR 2026
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the three key mechanisms
03-18 04:37
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Needham Reiterates Buy on Immuneering, Maintains $11 Price Target
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $11 price target.
03-09 17:52
Immuneering Q4 EPS $(0.18) Beats $(0.31) Estimate
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 42.31 percent. This is a 68.97 percent increase over losses of $(0.58) per share from the
03-06 20:48
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
01-07 23:03
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-12-25 00:06
Immuneering To Provide 12-Month Overall Survival From Its Current Phase 2a Clinical Study Of Atebimetinib + Modified Gemcitabine In Pancreatic Participants
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at
2025-12-23 21:03
